Current Problems in Cancer
Volume 33, Issue 3 , Pages 168-193 , May 2009

Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Non-Colorectal Indications

  • Perry Shen, MD, FACS

      Affiliations

    • Associate Professor of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • John H. Stewart IV, MD, FACS

      Affiliations

    • Assistant Professor of Surgery, Director of the Tumor Immunotherapy Program, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Edward A. Levine, MD, FACS

      Affiliations

    • Professor of Surgery, Chief of Surgical Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

References 

  1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–363
  2. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42
  3. Torisu M, Katano M, Kimura Y, Itoh H, Takesue M. New approach to management of malignant ascites with a streptococcal preparation OK 432 (I. Improvement of host immunity and prolongation of survival). Surgery. 1983;93:357–364
  4. Hendren SK, Hahn SM, Spitz FR, Bauer TW, Rubin SC, Zhu T, et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol. 2001;8:65–71
  5. Sindelar WF, DeLaney TF, Tochner Z, Thomas GF, Dachoswki LJ, Smith PD, et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms (Phase I study). Arch Surg. 1991;126:318–324
  6. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–132
  7. Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 2000;88:2512–2519
  8. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg. 2000;66:561–568
  9. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–3743
  10. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43
  11. Markman M, Walker JL. Intraperitoneal chemotherapy in ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006;24:988–994
  12. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–308
  13. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, et al. Pseudomyxoma peritonei (Long-term patient survival with an aggressive regional approach). Ann Surg. 1994;219:112–119
  14. Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg. 1998;85:1332–1339
  15. Cannistra SA. Intraperitoneal chemotherapy comes of age. N Engl J Med. 2006;354:77–79
  16. Stewart JH, Shen P, Russell GB, Bradley RF, Hundley JC, Loggie BW, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–634
  17. Bradley RF, Stewart JH, Russell G, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 uniformly treated patients at a single institution, with literature review. Am J Surg Pathol. 2006;30:551–559
  18. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33
  19. Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178–186
  20. Hall JJ, Loggie BW, Shen P, Beamer S, Case LD, McQuellon R, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004;8:454–463
  21. Jacks SP, Hundley JC, Shen P, Russell GB, Levine EA. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol. 2005;91:112–117
  22. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999–1003
  23. Levine EA. Problems of success and problems of failure: recurrent disease after cytoreductive surgery and intraperitoneal chemoperfusion. Ann Surg Oncol. 2004;11:351–353
  24. AJCC. Cancer Staging Manual. 6th edn.. New York, NY: Springer-Verlag; 2002;
  25. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480–487
  26. Dedrick RL. Interspecies scaling of regional drug delivery. J Pharmacol Sci. 1986;75:1047–1052
  27. Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol. 1985;248:F413–F424
  28. Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46:685–689
  29. Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40:567–572
  30. Israel VK, Jiang C, Muggia FM, Tulpule A, Jeffers S, Leichman L, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol. 1995;37:32–38
  31. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42:4265–4269
  32. Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 1998;83:1251–1261
  33. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–550
  34. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:2620–2624
  35. Stewart JH, Shen P, Russell G, Fenstermaker J, McWilliams L, Coldrun FM, et al. A phase I trial of intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination of colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15:2137–2145
  36. Dikomey E, Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol. 1992;61:221–233
  37. Roti JL, Kampinga HH, Malyapa RS, Wright WD, vander Waal RP, Xu M. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones. 1998;3:245–255
  38. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res. 1980;40:1165–1168
  39. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41:147–154
  40. Los G, Smals OA, van Vugt MJ, van der Vlist M, den Englase L, McVie JG, et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 1992;52:1252–1258
  41. van Ruth S, Acherman YI, van de Vijver MJ, Hart AA, Verwaal VJ, Zoetmulder FA. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol. 2003;29:682–688
  42. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–228
  43. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–731
  44. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg. 2001;88:458–463
  45. Elias D, Laurent S, Antoun S, Duvillard P, Ducreux M, Pocard M, et al. Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2003;27:407–412
  46. Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11:393–398
  47. Culliford AT, Brooks AD, Sharma S, Saltz LB, Schwartz GK, O'Reilly EM, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol. 2001;8:787–795
  48. Marcus EA, Weber TK, Rodriguez-Bigas MA, Driscoll D, Meropol NJ, Petrelli NJ. Prognostic factors affecting survival in patients with colorectal carcinomatosis. Cancer Invest. 1999;17:249–252
  49. Glehen O, Kwiakowski F, Sugarbaker PH, Elias D, Levine EA, de Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–3292
  50. Esquivel J, Sugarbaker P, Sticca R, Levine EA, Yan TD, Alexander R, et al. Consensus statement for cytoreductive surgery and intraperitoneal chemotherapy for colorectal carcinoma. Ann Surg Oncol. 2007;14:128–133
  51. Kelly JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1–9
  52. Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L, et al. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol. 2001;27:125–134
  53. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988;61:232–237
  54. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999;85:529
  55. Yonemura Y, Fujimura T, Nishimura G, Falla R, Sawa T, Katayama K, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery. 1996;119:437–444
  56. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71–76
  57. Sayag-Beaujard AC, Francois Y, Glehen O, Sadeghi-Looyeh B, Bienvenu J, Panteix G, et al. Intraperitoneal chemohyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Anticancer Res. 1999;19:1375–1382
  58. Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer. 1990;65:65–71
  59. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg. 2001;25:985–990
  60. Blair SL, Chu DZJ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol. 2001;8:632–637
  61. Hribaschek A, Kuhn R, Pross M, Lippert H, Halangk W, Boltze C, et al. Prophylaxis of peritoneal carcinomatosis in experimental investigations. Int J Colorectal Dis. 2001;16(5):340–345
  62. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20
  63. MacDonald JS, Smalley R, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–729
  64. Kaibara N, Hamazoe R, Iitsuka Y, Maeta M, Koga S. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterology. 1989;36:75–78
  65. Tahara M, Ohtsu A, Boku N, Nagashima F, Muto M, Sano Y, et al. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer. 2001;4:212–218
  66. Yonemura Y, Ninomiya I, Kaji M, Sugiyama K, Fujimura K, Sawa T, et al. Prophylaxis with intraperitoneal chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg. 1995;19:450–455
  67. Nomura E, Niki M, Fujii K, Shinohara H, Nishiguchi K, Sonoda T, et al. Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer. 2001;4:75–82
  68. Yan TD, Black D, Sugarbaker PH, Zhu J, Yoneura Y, Petrou G, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14:2702–2713
  69. Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T, et al. Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg. 2005;9:1346–1353
  70. Glehen O, Schreiber V, Cotte E, Syag-Beaujard AC, Osinsky D, Freyer G, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139:20–26
  71. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matuski N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthemic peritoneal perfusion. Br J Surg. 2005;92:370–375
  72. Talamonti MS, Goetz LH, Rao S, Joehl RJ. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg. 2002;137:564–570
  73. Brucher BL, Roder JD, Fink U, Stein HJ, Busch R, Siewert JR. Prognostic factors in resected primary small bowel tumors. Digest Surg. 1998;15:42–51
  74. North JH, Pack MS. Malignant tumors of the small intestine: a review of 144 cases. Am Surg. 2000;66:46–51
  75. Frost DB, Mercado PD, Tyrell JS. Small bowel cancer: a 30-year review. Ann Surg Oncol. 1994;1:290–295
  76. Marchettini P, Sugarbaker PH. Mucinous adenocarcinoma of the small bowel with peritoneal seeding. Eur J Surg Oncol. 2002;28:19–23
  77. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200
  78. Alberts DS, Lui PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophophamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  79. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–1007
  80. Armstrong DK, Bundy BN, Baergen R, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group Trial. Proc Am Soc Clin Oncol. 2002;21:201a;(abst 803)
  81. Speyer JL, Beller U, Colombo N, Sorich J, Wernz JC, Hochster H, et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol. 1990;8:1335–1341
  82. Pfeiffer P, Bennedaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol. 1990;36:306–311
  83. Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol. 2008;98:283–290
  84. Lentz S, Miller BE, Kucera GL, Levine EA. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol. 2007;106:207–210
  85. Digiorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315–325
  86. Sridhar K, Doria R, Raub W, Thurer R, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer. 1992;70:2969–2979
  87. Wagner J, Sleggs C, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–271
  88. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603
  89. Chailleux E, Dabouis G, Pioche D, de Lajartre M, de Lajartre A, Rembeaus A, et al. Prognostic factors in diffuse malignant pleural mesothelioma (A study of 167 patients). Chest. 1988;93:159–162
  90. Pass H, Kranda K, Temeck B, Feuerstein I, Steinberg S. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol. 1997;4:215–222
  91. Janne P. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer. 2003;5:98–106
  92. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988;6:147–153
  93. Ribak J, Lilus R, Suzuki Y, Penner L, Selikoff I. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and cause of death. Br J Ind Med. 1998;45:182–187
  94. Trupiano JK, Geisinger KM, Willingham MD, Manders P, Zbieranski N, Case D, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004;17:476–481
  95. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–4567
  96. Park BJ, Alexander R, Lubutti SK, Wu P, Royalty D, Kranda KC, et al Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion. Ann Surg Oncol. 1999;6:582–590
  97. Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–1661
  98. Yan T, Welch L, Black D, Sugarbaker P. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827–834
  99. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (HIPEC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73
  100. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–162
  101. Alexander HR, Mavroukakis SM, Libutti SK, Pingpank JF, Beresnev TH, Marden S, et al. Impact of tumor resection and intraperitoneal chemotherapy on health related quality of life in patients with peritoneal surface malignancies. Proceedings of the 57th Annual Society of Surgical Oncology Cancer Symposium, 2004.
  102. Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg. 1999;23:23–29
  103. Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518–521

PII: S0147-0272(09)00029-4

doi: 10.1016/j.currproblcancer.2009.06.005

Current Problems in Cancer
Volume 33, Issue 3 , Pages 168-193 , May 2009

Article Tools

* Image Usage & Resolution